TFA
VKTX icon

Transamerica Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

Transamerica Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429 Buy
11
+5
+83% +$162 ﹤0.01% 1719
2026
Q1 		$195 Buy
6
+1
+20% +$32 ﹤0.01% 1638
2025
Q4 		$176 Hold
5
– – ﹤0.01% 1558
2025
Q3 		$131 Buy
+5
New +$149 ﹤0.01% 1493

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Transamerica Financial Advisors's VKTX Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Viking Therapeutics (VKTX) stake by 83% in Q2 2026, buying an estimated $162 and bringing the position to 11 shares worth $429. The position accounts for ﹤0.01% of the portfolio, ranked #1719.

Transamerica Financial Advisors first reported a position in VKTX in Q3 2025 and has held it in 4 quarters since. 433 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Transamerica Financial Advisors held 11 shares of Viking Therapeutics worth $429 as of Q2 2026.
  • Transamerica Financial Advisors bought 5 Viking Therapeutics shares in Q2 2026, an estimated $162.
  • Viking Therapeutics made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #1719 holding.
  • Transamerica Financial Advisors first reported a position in Viking Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 433 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.